QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study

Trial Profile

QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Capsaicin (Primary) ; Pregabalin
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms ELEVATE
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 19 Nov 2015 According to an Astellas Pharma media release, results from this trial were published in the European Journal of Pain.
    • 19 Nov 2015 Primary endpoint [Proportion of subjects in each arm who achieve at least 30% decrease in the average pain for the past 24 hours Numeric Pain Rating Scale (NPRS) score from baseline to week 8] has been met, according to an Astellas Pharma media release.
    • 19 Nov 2015 Results were published in an Astellas Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top